1098189-15-1

Basic information

• Product Name: vedroprevir
• CAS NO: 1098189-15-1
• Molecular Weight: 910.532
• Mol File: 1098189-15-1.mol
• Article Data: 2

Chemical Properties

• Density: 1.38±0.1 g/cm3(Predicted)
• CAS DataBase Reference: vedroprevir(CAS DataBase Reference)
• NIST Chemistry Reference: vedroprevir(1098189-15-1)
• EPA Substance Registry System: vedroprevir(1098189-15-1)

Safety Data

• Hazardous Substances Data: 1098189-15-1(Hazardous Substances Data)

Usage

Description

Vedroprevir, also known as GS-9900, is a direct-acting antiviral medication specifically designed to target and inhibit the hepatitis C virus (HCV). It is a linear, non-immunogenic, and non-competitive inhibitor of the HCV NS5A protein, which plays a crucial role in the virus's replication, assembly, and secretion. Vedroprevir's unique mechanism of action makes it an effective treatment option for patients with HCV genotype 1 infection.

Uses

Used in Pharmaceutical Industry:
Vedroprevir is used as an antiviral agent for the treatment of hepatitis C virus (HCV) in patients with HCV genotype 1 infection. It works by inhibiting the NS5A protein, which is essential for the virus's replication, assembly, and secretion. This inhibition helps to reduce the viral load and prevent the progression of the disease, ultimately leading to improved patient outcomes and a higher chance of achieving a sustained virological response (SVR).
In addition to its primary application, vedroprevir may also be studied for potential use in combination therapies with other antiviral medications to enhance the treatment of hepatitis C virus infections, particularly in cases where resistance to current treatments is observed. This could further expand the drug's applications and improve the overall effectiveness of HCV treatment regimens.

Upstream product

• 1098189-05-9 2-isopropylamino-thiazole-4-carboxylic acid [6-acetyl-2-chloro-3-(2,2-dimethoxy-ethoxy)phenyl]amide 
• 438452-29-0 1-tert-butyl 2-methyl (2S,4S)-4-{[(4-bromo-phenyl)sulfonyl]oxy}-pyrrolidine-1,2-dicarboxylate 
• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 
• 694-43-9 (1R,3r,5S)-bicyclo[3.1.0]hexan-3-ol 
• 1001155-58-3 C₁₂H₁₄BrNO₅S 
• 1098181-41-9 C₂₂H₃₁BrN₂O₈S 
• 1098198-75-4 carbonic acid bicyclo[3.1.0]hex-3-yl ester 2,5-dioxo-pyrrolidin-1-yl ester 
• 1098189-14-0 C₄₆H₆₂ClN₇O₉S 
• 1098189-11-7 C₄₂H₅₃ClN₆O₉S 
• 1098189-09-3 C₄₄H₅₉ClN₆O₁₀S 
• 1098189-06-0 C₁₉H₂₂ClN₃O₄S 
• 1098189-01-5 1-[2-amino-3-chloro-4-(2,2-dimethoxy-ethoxy)-phenyl]-ethanone 
• 1098189-00-4 1-(2-amino-3-chloro-4-hydroxy-phenyl)-ethanone 
• 1098189-07-1 C₃₁H₄₂BrN₃O₉S 

Relevant articles and documents

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.